JH
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.$12.25 +0.00 (+0.00%)
Oct 26 4:00 PM ET · prev $12.25
Since first trade
−28.5%
from $17.14 · Apr 22
30 days
+6.5%
from $11.50
Range since listing
$11.50–20.00
−39% from high · low Sep 15
Avg volume 20D
36
Oct 5 spike 211
Short interest
🔒 Subscribers only
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- E Oct 12 Trial readout: Results Pending: HRS-9190; under Inhalational Anesthesia (…
- E Oct 19 Trial readout: T-90d Trial Readout: SHR-A1811 (Phase 3)
- E Oct 19 Trial readout: T-90d Trial Readout: SHR-A1811 (Phase 2)
- E Oct 19 Trial readout: T-90d Trial Readout: Fuzuloparib , Abiraterone acetate and…
- E Oct 22 Trial readout: Results Pending: HRS-8427 (Phase 2) — Completed 30d ago
- E Oct 24 Trial readout: Results Pending: Tegileridine Fumarate lnjection (Phase 2)…
- E Oct 24 Trial readout: Results Pending: Herombopag tablets (Phase 3) — Completed…
- E Oct 26 Trial readout: T-90d Trial Readout: SHR-A1811 (Phase 3)
Signal stack
Where each data set points today.
- TrendRANGE
15% below its 50-day average.
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 Clinical trial readout
T-90d Trial Readout: SHR-A1811 (Phase 3)
Trial: A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unres
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 26, 2026
Trial readout
T-90d Trial Readout: SHR-A1811 (Phase 3)
Trial: A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects…
Oct 24, 2026
Trial readout
Results Pending: Tegileridine Fumarate lnjection (Phase 2) — Completed 71d ago
Trial: A Trial of Tegileridine Fumarate Lnjection for Prolonged Mechanical Ventilation Abirritation in the Intensive Care Unit (ICU) Sponsor…
Oct 24, 2026
Trial readout
Results Pending: Herombopag tablets (Phase 3) — Completed 71d ago
Trial: The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective…
Oct 23, 2026
Clinical Trial
A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Adults
Phase 3 · COMPLETED
Oct 22, 2026
Trial readout
Results Pending: HRS-8427 (Phase 2) — Completed 30d ago
Trial: A Trial of HRS-8427 in the Treatment of Adults With Bacterial Pneumonia Sponsor: Jiangsu HengRui Medicine Co., Ltd. Phase: Phase 2 |…
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | — | — | — | $33.6B |
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 15, 2026🔒 Subscribers only
shares short